AGA-2115 by Angitia Biopharmaceuticals for Osteogenesis Imperfecta: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AGA-2115 overview
AGA-2115 is under development for the treatment of osteogenesis imperfecta (OI). It is a bi-specific monoclonal antibody which acts by targeting sclerostin and dickkopf-1 related protein 1 (DKK1). It is administered through subcutaneous and intravenous route.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Angitia Biopharmaceuticals overview
Angitia Biopharmaceuticals is a developer of new drugs intended to solve orthopedic issues. The company is headquartered in Guangzhou, Guangdong, China.
For a complete picture of AGA-2115’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#AGA2115 #Angitia #Biopharmaceuticals #Osteogenesis #Imperfecta #Likelihood #Approval
